Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 20,000 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMAGet Free Report) Director Cyrus Harmon sold 20,000 shares of the stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $10.97, for a total transaction of $219,400.00. Following the transaction, the director now owns 826,283 shares in the company, valued at approximately $9,064,324.51. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Cyrus Harmon also recently made the following trade(s):

  • On Thursday, February 29th, Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $12.41, for a total transaction of $310,250.00.
  • On Wednesday, January 31st, Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $12.23, for a total transaction of $305,750.00.

Olema Pharmaceuticals Price Performance

Shares of Olema Pharmaceuticals stock opened at $11.32 on Friday. Olema Pharmaceuticals, Inc. has a fifty-two week low of $3.00 and a fifty-two week high of $17.79. The firm has a fifty day moving average price of $13.17 and a two-hundred day moving average price of $13.11.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on OLMA. Citigroup began coverage on shares of Olema Pharmaceuticals in a report on Tuesday, January 30th. They set a “buy” rating and a $20.00 price objective for the company. Capital One Financial reaffirmed an “overweight” rating on shares of Olema Pharmaceuticals in a report on Thursday, February 22nd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $21.00.

Read Our Latest Stock Analysis on Olema Pharmaceuticals

Institutional Trading of Olema Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Olema Pharmaceuticals by 9.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,951 shares of the company’s stock valued at $224,000 after purchasing an additional 1,367 shares during the period. Royal Bank of Canada lifted its holdings in shares of Olema Pharmaceuticals by 682.4% during the 2nd quarter. Royal Bank of Canada now owns 2,801 shares of the company’s stock worth $25,000 after acquiring an additional 2,443 shares during the period. Public Employees Retirement System of Ohio bought a new position in shares of Olema Pharmaceuticals during the 3rd quarter worth about $35,000. SG Americas Securities LLC lifted its holdings in shares of Olema Pharmaceuticals by 38.1% during the 4th quarter. SG Americas Securities LLC now owns 15,874 shares of the company’s stock worth $223,000 after acquiring an additional 4,379 shares during the period. Finally, Rhumbline Advisers lifted its holdings in shares of Olema Pharmaceuticals by 14.5% during the 3rd quarter. Rhumbline Advisers now owns 37,840 shares of the company’s stock worth $467,000 after acquiring an additional 4,787 shares during the period. 91.78% of the stock is owned by institutional investors.

Olema Pharmaceuticals Company Profile

(Get Free Report)

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer.

Read More

Insider Buying and Selling by Quarter for Olema Pharmaceuticals (NASDAQ:OLMA)

Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.